Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Bitdeer Technologies Group (BTDR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Bitdeer Technologies Group — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Bitdeer Technologies Group trades at $12.82 (market cap $3.23B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 12.3× Bitdeer Technologies Group's market cap, and Bitdeer Technologies Group is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | BTDR | |
|---|---|---|
Market Cap | $39.89B | $3.23B |
Sector | Health | Technology |
52-Week High | $491.22 | $25.90 |
52-Week Low | $278.09 | $7.28 |
Enterprise Value | $38.15B | $5.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
BTDR trades at $13.29, down 7.26% in the last 24 hours, with a bearish technical signal and recent earnings misses. The company reported revenue growth to $620.25 million in 2025 but a net income margin of -26.96% in 2026, indicating profitability challenges. Positive developments include expansion into AI cloud infrastructure and new facility openings, yet negative cash flow from operations persists.
The outlook is mixed: strong analyst buy consensus (81.82%) and a $23.40 price target suggest upside, but operational losses and Bitcoin market volatility pose significant risks. Investment opportunity lies in AI infrastructure growth, while execution and sector headwinds require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Bitdeer Technologies Group
Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.
Read more on BTDR →
